GlassScriptPhysician profile
Lauren E Tarbox
NPI 1154580223
$28,107.68
in general payments reported to CMS, 2019-2025
32 companies · $16K in 2025
The $16K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $232 · 2021: $921 · 2022: $1,474 · 2023: $1,752 · 2024: $7,056 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $7,181 · Consulting Fee: $1,500 · Travel and Lodging: $425 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,500.00 |
| Food and Beverage | $7,181.01 |
| Consulting Fee | $1,500.00 |
| Travel and Lodging | $424.76 |
| Education | $146.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $18,261.93 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Astrazeneca Pharmaceuticals LP | $2,139.24 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $1,205.16 | 2019-2025 | Rayaldee |
| Amgen INC. | $747.74 | 2019-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $673.43 | 2019-2025 | Jynarque |
| Akebia Therapeutics INC | $584.57 | 2021-2025 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $569.42 | 2021-2025 | |
| Travere Therapeutics, INC. | $552.09 | 2022-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $442.50 | 2021-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $404.37 | 2020-2025 | Acthar |
| Calliditas Therapeutics US INC. | $243.17 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $241.97 | 2024-2025 | |
| Vifor Pharma, INC. | $241.06 | 2022-2025 | Veltassa, Korsuva |
| Corcept Therapeutics | $232.65 | 2025 | Korlym |
| Horizon Therapeutics Plc | $230.88 | 2019-2023 | Krystexxa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $216.21 | 2019-2024 | Velphoro, Korsuva |
| Lilly USA, LLC | $141.33 | 2023-2024 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $141.05 | 2022-2024 | Benlysta, Jesduvroq |
| Mallinckrodt Enterprises LLC | $123.51 | 2019 | |
| Novo Nordisk INC | $117.12 | 2024 | |
| Cormedix INC. | $94.43 | 2024 | Defencath |
| Baxter Healthcare | $86.34 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.40 | 2024-2025 | Jardiance |
| Nxstage Medical, INC. | $69.45 | 2019 | |
| Apellis Pharmaceuticals, INC. | $57.21 | 2025 | |
| Inari Medical, INC. | $53.54 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Takeda Pharmaceuticals U.S.A., INC. | $49.58 | 2021-2024 | Gattex |
| Scpharmaceuticals INC. | $33.90 | 2025 | |
| Globus Medical, INC. | $27.04 | 2025 | Senza |
| Ani Pharmaceuticals, INC. | $21.25 | 2025 | Purified Cortrophin Gel |
| Amicus Therapeutics, INC. | $21.18 | 2020 | |
| Amarin Pharma, INC. | $13.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Tarbox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.